Skip to main content

Advertisement

SpringerLink
Log in

Interleukin 6 and complement serum level study in Parkinson’s disease

  • Neurology and Preclinical Neurological Studies - Original Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

The objective of this study is to assess whether elevation of serum inflammatory markers levels may indicate the progression of clinical impairment in Parkinson’s disease (PD) patients. In 47 PD patients, the serum levels of the C3 and C4 part of the complement and Interleukin-6 (IL-6) were measured. The results at baseline and after 2 years were correlated with scales measuring memory, depression, motor symptoms, and quality of life. Patients with higher levels of C3 and C4 at baseline had decreased quality of life, verbal ability, and memory. Patients with higher IL-6 at baseline showed worse depression scores at 2 years. Patients with persistently higher levels of C3 and C4 at 2 years had worse quality of life and memory ability. Uncorrected p values are reported due to the exploratory nature of the study. The results indicate an impact of inflammation on non-motor signs and quality of life in PD. The increase of levels of serum inflammatory biomarkers may indicate the progression of non-motor impairment in PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

ACE:

Addenbrooke’s cognitive examination

ADL:

Activity of Daily Living Scale

BI:

Barthel Index

BVRT:

Benton visual retention test

CDT:

Clock drawing test

CSF:

Cerebrospinal fluid

ECLIA:

Electrochemiluminescence immunoassay

H–Y:

Hoehn–Yahr Scale

IL-6:

Interleukin 6

MADRS:

Montgomery Asberg Depression Rating Scale

MMSE:

Mini-mental state examination

PD:

Parkinson’s disease

UPDRS:

Unified Parkinson’s Disease Rating Scale

VFT:

Verbal fluency test

WMS:

Wechsler Memory Scale

References

  • Auriacombe S, Grossman M, Carvell S, Gollomp S (1993) Verbal fluency deficits in Parkinson’s disease. Neuropsychology 7:182–192

    Article  Google Scholar 

  • Benton AL (1983) Contributions to neuropsychological assessment. Oxford University Press, New York

    Google Scholar 

  • Berczi I, Quintanar-Stephano A, Kovacs K (2009) Neuroimmune regulation in immunocompetence, acute illness, and healing. Ann N Y Acad Sci 1153:220–239

    Article  CAS  PubMed  Google Scholar 

  • Bonifati DM, Kishore U (2007) Role of complement in neurodegeneration and neuroinflammation. Mol Immunol 44:999–1010

    Article  CAS  PubMed  Google Scholar 

  • Brodacki B, Staszewski J, Toczyłowska B, Kozłowska E, Drela N, Chalimoniuk M, Stepien A (2008) Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNF-alpha, and IFNgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett 441:158–162

    Article  CAS  PubMed  Google Scholar 

  • Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW (1999) Association of circulating TNF-alpha and IL-6 with aging and parkinsonism. Acta Neurol Scand 100:34–41

    Article  CAS  PubMed  Google Scholar 

  • Dufek M, Hamanová M, Lokaj L, Goldemund D, Rektorová I, Michálková Z, Sheardová K, Rektor I (2009) Serum inflammatory biomarkers in Parkinson’s disease. Parkinsonism Relat Disord 15:318–320

    Article  CAS  PubMed  Google Scholar 

  • Dufek M, Rektorová I, Thon V, Lokaj L, Rektor I (2015) Interleukin-6 may contribute to mortality in Parkinson’s disease patients: a 4 year prospective study. Parkinson’s Dis 2015:898192

    Google Scholar 

  • Dunn AJ (2006) Effects of cytokines and infections on brain neurochemistry. Clin Neurosci Res 6:52–68

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fahn S, Elston RL, Members of the UPDRS Development Committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinson’s disease, vol 2. Macmillan, New York, pp 153–163

    Google Scholar 

  • Finehout EJ, Franck Z, Lee KH (2005) Complement proteins isoforms in CSF as possible biomarkers for neurodegenerative diseases. Dis Markers 11:93–101

    Article  Google Scholar 

  • Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198

    Article  CAS  PubMed  Google Scholar 

  • Freedman M, Kaplan E, Delis D, Morris R (1994) Clock drawing: a neuropsychological analysis. Oxford University Press, New York

    Google Scholar 

  • Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442

    Article  CAS  PubMed  Google Scholar 

  • Hoffmann KW, Schuh Schumacher AF, SauteJ Townsend R, Fricke D, Leke R, Souza DO, Valmor Portela L, Fagundes Chaves ML, Rieder CRM (2009) Interleukin-6 serum levels in patients with Parkinson’s disease. Neurochem Res 34:1401–1404

    Article  Google Scholar 

  • Honglei C, Shumin M, Ascherio A (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60:1059–1064

    Article  Google Scholar 

  • Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kang Sujin, Tanaka Toshio, Kishimoto Tadamitsu (2015) Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol 27(1):21–29

    Article  CAS  PubMed  Google Scholar 

  • Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179–186

    Article  CAS  PubMed  Google Scholar 

  • Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O (2012) Nonmotor symptoms in patients with Parkinson’s disease—correlations with inflammatory cytokines in serum. PLoS One 7:e47387

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O (2013) Cerebrospinal fluid inflammatory markers in Parkinson’s disease-associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 33:183–189

    Article  CAS  PubMed  Google Scholar 

  • Mahoney FI, Barthel DW (1965) Functional evaluation: the BARTHEL index. MD State Med J 14:61–65

    CAS  PubMed  Google Scholar 

  • Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T (1994) Interleukin-1beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147–150

    Article  CAS  PubMed  Google Scholar 

  • Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming factor levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Neurosci Lett 211:13–16

    Article  CAS  PubMed  Google Scholar 

  • Montgomery SA, Asberg MA (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389

    Article  CAS  PubMed  Google Scholar 

  • Müller T, Blum-Degen D, Przuntek H, Kuhn W (1998) Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson’s disease. Acta Neurol Scand 98:142–144

    Article  PubMed  Google Scholar 

  • Olson KE, Gendelman HE (2016) Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson’s disease. Curr Opin Pharmacol 26:87–95

    Article  CAS  PubMed  Google Scholar 

  • Pålhagen S, Qi H, Mårtensson B, Wålinder J, Granérus AK, Svenningsson P (2010) Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson’s disease and major depression. J Neurol 257:524–532

    Article  PubMed  Google Scholar 

  • Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y (2016) Aberrations in peripheral inflammatory cytokine levels in Parkinson’s disease: a systematic review and meta-analysis. JAMA Neurol 73:1316–1324

    Article  PubMed  Google Scholar 

  • Reyes MA, Perez-Lloret SP, Roldan Gerscovich EG, Martin ME, Leiguarda R, Merello M (2009) Addenbrooke’s Cognitive Examination validation in Parkinson’s disease. Eur J Neurol 16:142–147

    Article  CAS  PubMed  Google Scholar 

  • Santangelo G, Vitale C, Picillo M, Moccia M, Cuoco S, Longo K, Barone P (2015) Mild Cognitive Impairment in newly diagnosed Parkinson’s disease: a longitudinal prospective study. Parkinsonism Relat Disord 21:1219–1226

    Article  PubMed  Google Scholar 

  • Scalzo P, Kümmer A, Cardoso F, Teixeira AL (2010) Serum levels of interleukin-6 are elevated in patients with Parkinson’s disease and correlate with physical performance. Neurosci Lett 468:56–58

    Article  CAS  PubMed  Google Scholar 

  • Schwab C, Steele JC, McGeer PL (1996) Neurofibrillary tangles of Guam Parkinson-dementia are associated with reactive microglia and complement proteins. Brain Res 707:196–205

    Article  CAS  PubMed  Google Scholar 

  • Umemura A, Oeda T, Yamamoto K (2015) Baseline plasma C-reactive protein concentrations and motor prognosis in Parkinson disease. PLoS One 10(8):0136722

    Google Scholar 

  • Wechsler D (1997) Wechsler memory scale the third edition, WMS-III. The Psychological Corporation, San Antonio

    Google Scholar 

  • Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans JR, ICICLE-PD Study Group et al (2016) Serum immune markers and disease progression in an incident Parkinson’s disease cohort (ICICLE-PD). Mov Disord 31(7):995–1003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yamada T, McGeer PL, McGeer EG (1992) Lewy bodies in Parkinson’s disease recognized by antibodies to complement proteins. Acta Neuropathol 84:100–104

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank to Prof. Egon Kurča, M.D., Ph.D., FESO, Prof. Peter Valkovič, M.D., Ph.D., and Ján Necpal, M.D., for kindly referring their patients for participation in this study and to Anne Johnson for grammatical assistance.

Funding

The study was supported by the Ministry of Education, Youth and Sports of the Czech Republic under the Project CEITEC 2020 (LQ1601).

Author information

Authors and Affiliations

  1. Department of Neurology, Faculty Hospital, Constantine the Philosopher University, Špitálska 6, 94901, Nitra, Slovak Republic

    Branislav Veselý & Miroslav Brozman

  2. Movement Disorders Center, First Department of Neurology, Masaryk University, St. Anne’s University Hospital, Pekařská 664/53, 656 91, Brno, Czech Republic

    Michal Dufek & Ivan Rektor

  3. Central European Institute of Technology (CEITEC), Brain and Mind Research Programme, 625 00, Brno, Czech Republic

    Branislav Veselý & Ivan Rektor

  4. Department of Clinical Immunology and Allergy, Faculty of Medicine, Masaryk University, St. Anne’s University Hospital, 656 91, Brno, Czech Republic

    Vojtech Thon

  5. Department of Clinical Psychology, Faculty Hospital, Constantine the Philosopher University, Špitálska 6, 94901, Nitra, Slovak Republic

    Silvia Királová & Tatiana Halászová

  6. Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 123/3, 625 00, Brno, Czech Republic

    Eva Koriťáková

Authors
  1. Branislav Veselý
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michal Dufek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vojtech Thon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miroslav Brozman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Silvia Királová
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tatiana Halászová
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eva Koriťáková
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ivan Rektor
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

BV: research project: conception, organization, execution; statistical analysis: review and critique; manuscript: writing of the first draft. MD: research project: execution; manuscript: review and critique. VT: research project: execution; manuscript: review and critique. EK: statistical analysis: design, execution, review and critique. MB: research project: execution. SK: research project: execution. TH: research project: execution. IR: research project: conception, organization, execution; statistical analysis: design; manuscript: review and critique.

Corresponding author

Correspondence to Ivan Rektor.

Ethics declarations

Conflict of interest

None of the authors report any conflict of interest or financial disclosure.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Veselý, B., Dufek, M., Thon, V. et al. Interleukin 6 and complement serum level study in Parkinson’s disease. J Neural Transm 125, 875–881 (2018). https://doi.org/10.1007/s00702-018-1857-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-018-1857-5

Keywords

Search

Navigation